Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity

被引：2
|
作者：
Choi, Sung Hee [1 ,2 ]
Myers, Jay Thomas [1 ]
Tomchuck, Suzanne Louise [1 ]
Bonner, Melissa [3 ]
Eid, Saada [1 ]
Kingsley, Daniel Tyler [3 ]
Vanheyst, Kristen Ashley [1 ,2 ]
Kim, Seong-Jin [4 ]
Kim, Byung-Gyu [1 ,2 ]
Huang, Alex Yee-Chen [1 ,2 ,3 ,5 ]
机构：
[1] Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH USA
[2] Case Western Reserve Univ, Case Comprehens Canc Ctr, Sch Med, Cleveland, OH USA
[3] Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH USA
[4] MedPacto Inc, Seoul, South Korea
[5] Rainbow Babies & Childrens Hosp, Angie Fowler AYA Canc Inst, Ctr Pediat Immunotherapy, Cleveland, OH USA
来源：
CANCER COMMUNICATIONS | 2024年 / 44卷 / 08期
关键词：
D O I：
10.1002/cac2.12589
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：884 / 888
页数：5
相关论文
共 50 条
  • [1] Oral TGF-beta receptor1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity
    Choi, Sung Hee
    Myers, Jay
    Tomchuck, Suzanne
    Bonner, Melissa
    Eid, Saada
    Kingsley, Daniel
    VanHeyst, Kristen
    Kim, Seong-Jin
    Kim, Byung-Gyu
    Huang, Alex Y.
    CANCER RESEARCH, 2024, 84 (06)
  • [2] Transforming growth factor-beta 1 is a major mediator of radioactive iodine therapy-induced anti-tumor immunity
    Stanciu, A. E.
    Panait, M. E.
    Hurduc, A. E.
    Zamfirescu, A.
    Stanciu, M. M.
    Cinca, S.
    FEBS JOURNAL, 2017, 284 : 280 - 280
  • [3] Safety and anti-tumor activity of the transforming growth factor β receptor I kinase inhibitor, vactosertib, in combination with pembrolizumab in patients with metastatic colorectal or gastric cancer
    Lee, Keun-Wook
    Park, Young Suk
    Ahn, Joong Bae
    Rha, Sun Young
    Kim, Hark Kyun
    Lee, Park Young
    Ryu, Min-Hee
    Lee, Jeeyun
    Lee, Jin Kyung
    Hwang, Sunjin
    Kiim, Seong-Jin
    Kim, Tae Won
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [4] Targeting SAMHD1 Promotes Anti-Tumor Immunity in Acute Myeloid Leukemia
    Zhang, Lei
    Dong, Haojie
    He, Xin
    Lin, Yichun
    Hu, Weidong
    Salhotra, Amandeep
    Armenian, Saro H.
    Marcucci, Guido
    Luo, Yun
    Li, Ling
    BLOOD, 2022, 140
  • [5] Safety and anti-tumor activity of the transforming growth factor β receptor I kinase inhibitor, vactosertib, in combination with durvalumab in patients with advanced non-small cell lung cancer (NSCLC)
    Han, Ji-Youn
    Pyo, Kyoung-Ho
    Kim, Jea Hwan
    Xin, Chun-Feng
    Lee, Jin Kyung
    Hwang, Sunjin
    Kim, Seong-Jin
    Cho, Byoung Chul
    Cho, Byoung Chul
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [6] Inhibition of hypoxia-inducible factor 1 (HIF-1)in tumor can augment anti-tumor immune responses in tumor-bearing mouse through suppression of transforming growth factor-beta (TGF-β)
    Teramoto, Koji
    Kawaguchi, You
    Hori, Tetsuo
    Kitamura, Shoji
    Hanaoka, Jun
    Tezuka, Noriaki
    Kontani, Keiichi
    CANCER RESEARCH, 2010, 70
  • [7] The mutant IDH1 inhibitor ivosidenib promotes tumor cell differentiation and anti-tumor immunity in intrahepatic cholangiocarcinoma
    Wu, Meng-Ju
    Shi, Lei
    Dubrot, Juan
    Hudson, Christine
    Merritt, Joshua
    Adil, Ramzi
    Wu, Qibiao
    Ronseaux, Sebastien
    Narayanaswamy, Rohini
    Manguso, Robert
    Nicolay, Brandon
    Bardeesy, Nabeel
    CANCER RESEARCH, 2020, 80 (16)
  • [8] miR-744-5p suppresses tumor proliferation and metastasis by targeting transforming growth factor-beta 1 (TGF-β1) in hepatocellular carcinoma (HCC)
    Huang, Weifeng
    Chen, Qingsong
    Dai, Jiangweng
    Zhang, Yuke
    Yi, Yan
    Wei, Xufu
    Wu, Zhongjun
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (04) : 1811 - 1822
  • [9] TRANSFORMING GROWTH-FACTOR-BETA - A NEW TYPE OF INHIBITOR OF PROLIFERATION OF NORMAL AND TUMOR-CELLS
    STOIKA, RS
    KUSEN, SI
    MOLECULAR BIOLOGY, 1990, 24 (04) : 738 - 748
  • [10] Inhibition of hypoxia-inducible factor 1 (HIF-1) in the tumor can augment anti-tumor immune responses through the elimination of transforming growth factor-beta (TGF-\#946;)-mediated immunosuppression
    Teramoto, Koji
    Igarashi, Tomoyuki
    Kitamura, Shoji
    Fujita, Takuya
    Hanaoka, Jun
    Tezuka, Noriaki
    Kontani, Keiichi
    Fujino, Shozo
    CANCER RESEARCH, 2009, 69
12345